South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.

The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.

Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.

Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator. 

Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.

Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.

The Dutch biotech's C-suite tells Scrip that the technology it has developed and now licensed to Genentech allows it to systematically go through the whole genome gene by gene and discover what the modifier of a particular disease is.

Scotland’s investment in regenerative medicine is paying off with two promising start-ups, one targeting liver disease, the other oncology, launching within days of each other.

The Indian regulator says it is not considering emergency use authorization for COVID-19 vaccines before completion of clinical trials, a stand validated by AstraZeneca halting trials of its vaccine candidate due to an adverse event in UK. Meanwhile, India has signed up for Phase III trials of Russia’s vaccine candidate

The healthcare giant's nasal spray for hard-to-treat depression has been rejected for use on the UK's NHS for a second time because of uncertainty over cost, but comments on this consultation could result in a change of fortunes for the potential blockbuster.

A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.

The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.

Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.

A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.

Teva’s market overhang and legal uncertainty intensifies with DOJ charges it conspired to fix generic drug prices. Five other companies have pled guilty and reached deferred prosecution agreements.

Facing an appeal on a favorable US district court decision, Mylan has opted to launch the first generic Tecfidera in the US “at risk,” after obtaining FDA approval and seeing Biogen’s bid for injunctive relief shot down earlier this month.

Annual large US employer health benefits survey also evaluates plans for managing the cost of cell and gene therapies in the coming years, anticipating growing use of outcomes-based contracts, but very limited uptake of payment-over-time models.

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.